Improving clinical outcomes for patients with cancer-associated thrombosis

Thrombosis and Haemostasis

Volumn 100, Issue 3, 2008, Pages 367-368

  Kakkar, Ajay ^a,b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CANCER PATIENT; DEEP VEIN THROMBOSIS; EDITORIAL; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COHORT STUDIES; HEMORRHAGE; HUMANS; NEOPLASMS; QUALITY OF LIFE; RECURRENCE; REGISTRIES; RESEARCH DESIGN; RISK; THROMBOSIS; TREATMENT OUTCOME; VITAMIN K;

EID: 51349095985     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th08-08-0517     Document Type: Editorial

References (6)

1. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
2. Levine MN. Can we optimise treatment of thrombosis? Cancer Treat Rev 2003; 29 (Suppl 2): 19-22.
3. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
4. Trujillo-Santos J, Nieto JA, Antonio J, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 435-439.
5. Khorana A, Kuderer MN, Culakova E, et al, Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
6. Zwicker JL. Tissue factor-bearing microparticles and cancer. Semin Thromb Hemost 2008; 34: 195-198.